Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Jadersten, M, Pellagatti, A, Forsblom, A, Emanuelsson, E, Merup, M, Samuelsson, J, Wainscoat, J, Boultwood, J, Hellstorm-Lindberg, E
Формат:	Conference item
Хэвлэсэн:	2005

Ижил төстэй зүйлс

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2006)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2007)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
-н: Jädersten, M, зэрэг
Хэвлэсэн: (2009)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
-н: Scharenberg, C, зэрэг
Хэвлэсэн: (2011)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
-н: Martin Jädersten, зэрэг
Хэвлэсэн: (2009-12-01)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2011)

Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion
-н: Martin Jädersten
Хэвлэсэн: (2010-03-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
-н: Nikpour, M, зэрэг
Хэвлэсэн: (2007)

Gene expression profiling in the myelodysplastic syndromes.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2005)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
-н: Raza Azra, зэрэг
Хэвлэсэн: (2012-04-01)

Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
-н: Lewis, S, зэрэг
Хэвлэсэн: (1995)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2009)

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion
-н: Maria Ximeri, зэрэг
Хэвлэсэн: (2010-03-01)

The impact of spliceosome mutations in MDS
-н: Jacqueline Boultwood, зэрэг
Хэвлэсэн: (2019-06-01)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2010)

5q- syndrome.
-н: Boultwood, J, зэрэг
Хэвлэсэн: (2012)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2010)

Clonality in the myelodysplastic syndromes.
-н: Boultwood, J, зэрэг
Хэвлэсэн: (2001)

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
-н: Caceres, G, зэрэг
Хэвлэсэн: (2013)

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide
-н: Gudrun Göhring, зэрэг
Хэвлэсэн: (2011-02-01)

The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
-н: Nilsson, L, зэрэг
Хэвлэсэн: (2007)

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
-н: Axel Rüfer, зэрэг
Хэвлэсэн: (2022-07-01)

Molecular pathogenesis of the myelodysplastic syndromes
-н: Boultwood, J, зэрэг
Хэвлэсэн: (1999)

Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide
-н: Virginie Eclache, зэрэг
Хэвлэсэн: (2008-02-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2003)

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2009)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
-н: Botezatu, L, зэрэг
Хэвлэсэн: (2016)

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide
-н: Bagi Jana, зэрэг
Хэвлэсэн: (2014-01-01)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2005)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
-н: Boultwood, J, зэрэг
Хэвлэсэн: (2012)

Telomere length in myelodysplastic syndromes.
-н: Boultwood, J, зэрэг
Хэвлэсэн: (1995)

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
-н: Pellagati, A, зэрэг
Хэвлэсэн: (2008)

Advances in the 5q- syndrome.
-н: Boultwood, J, зэрэг
Хэвлэсэн: (2010)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2004)

The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells
-н: Brigitte Mohr, зэрэг
Хэвлэсэн: (2009-03-01)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
-н: Yu Han Koh, зэрэг
Хэвлэсэн: (2023-08-01)

PP2A: The Achilles Heal in MDS with 5q Deletion
-н: David eSallman, зэрэг
Хэвлэсэн: (2014-09-01)